Impact of Triacetin- and Tributyrin-Based Formulations on IBS Microbiome Composition and SCFA Profiles: A Preclinical Study.

Liam Jenkins Sánchez, Jonas Poppe, Aurélien Baudot, Lam Dai Vu, Will Villella, Pieter Van den Abbeele

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Liam Jenkins SánchezCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.ORCID 0000-0002-2932-3191

Jonas PoppeCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.

Aurélien BaudotCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.ORCID 0009-0009-4872-6875

Lam Dai VuCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.

Will VillellaGundry MD®, 145 S. Fairfax Avenue, Suite 200, Los Angeles, CA 90036, USA.

Pieter Van den AbbeeleCryptobiotix SA, Technologiepark-Zwijnaarde 82, 9052 Ghent, Belgium.ORCID 0000-0002-1399-6332

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Irritable bowel syndrome (IBS) is a prevalent yet poorly understood functional gut disorder frequently associated with microbial dysbiosis, making microbiome-targeting interventions a promising management strategy. In this study, we evaluated the microbiome-modulating potential of three doses of triacetin (TA; ReBiome™; 100, 200 and 300 mg/day) and two finished formulations containing TA and/or tributyrin (TB): Active Biome™ (AB) and Bio Complete 3™ (BC3). Inulin served as a benchmark prebiotic. The validated ex vivo Systemic Intestinal Fermentation Research (SIFR

Indexed as

Fatty Acids, VolatileGastrointestinal MicrobiomeIrritable Bowel SyndromeTriacetinTriglyceridesAdultButyratesFecesFemaleFermentationHumansMalePrebioticsButyratesFatty Acids, VolatilePrebioticsTriacetintributyrinTriglyceridesirritable bowel syndrome (IBS)metagenomicsmicrobiomeSCFAsSystemic Intestinal Fermentation Research (SIFR®)triacetintributyrin

Identifiers

PMID42884152

DOI10.3390/ijms27198910

PMCPMC13665126

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.